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Abstract.  Two mAbs that are specific for heparan 
sulfate-related epitopes have been raised and used to 
analyze the cellular and tissular distribution of this 
glycosaminoglycan during development, mAb  10E4 
reacts with an epitope that occurs in native heparan 
sulfate chains and that is destroyed by N-desulfation of 
the glycosaminoglycan. The antibody does not react 
with hyaluronate,  chondroitin  sulfate, or DNA, and 
reacts only poorly with heparin.  The reactivity of pro- 
teoglycan extracts or tissue sections with the 10E4 an- 
tibody is completely abolished by heparitinase,  but is 
only partially affected by heparinase,  mAb 3G10,  in 
contrast,  reacts only with heparitinase-treated  heparan 
sulfate chains,  proteoglycans, or tissue sections.  The 
3G10 epitope is destroyed by treatment with mercuric 
acetate,  which indicates that the desaturated uronate 
generated by the lyase is essential for the reactivity of 
the antibody. The 3G10 epitope is not generated by 
treating heparan sulfate proteoglycans with heparinase 
or chondroitin  sulfate proteoglycans with chondroitin 
sulfate lyases, which indicates that the 3G10 antibody 
recognizes desaturated uronates that occur in specific 
structural contexts. The antibody  10E4 and,  after 
heparitinase treatment,  the antibody 3G10 decorate the 
surfaces of many cell types and the extracellular ma- 
trix in proximity of the cells, in particular,  the base- 
ment membranes.  The analysis of embryonic and adult 
tissues reveals important temporal and regional differ- 
ences in the abundance of the  10E4 and 3G10 epitopes 
at these sites.  Moreover, the staining pattern of the 
two antibodies is not always superimposable, which is 
indicative of regional differences in the exposure or 
structure of the tissular heparan  sulfates. As a whole 
the results suggest that heparan  sulfate abounds at sites 
of active morphogenesis and that the expression of this 
glycosaminoglycan is developmentally regulated. 
T 
HE heparan sulfate proteoglycans occur at the cell sur- 
face and in the extracellular  matrix in the immediate 
vicinity of the cells (GaUagher, 1989). These localiza- 
tions  are  assumed  to  be  dictated,  at  least  in  part,  by 
membrane- and matrix-anchoring  structures in the protein 
moieties of these molecules.  For human fetal fibroblastic 
cells,  for example,  this  has been supported by molecular 
cloning experiments,  which have identified  complementary 
DNA structures coding for core proteins with extended se- 
quences of hydrophobic amino acids that could function as 
membrane spanning domains (Marynen et al., 1989) and as 
signals for the attachment of a glycosyl phosphatidylinositol 
anchor (David et al., 1990), and by functional studies, which 
have documented a specific and high affinity binding interac- 
tion between fibronectin  and the core protein of the matrix- 
bound proteoglycan (Heremans et al.,  1990).  The expres- 
sion of at least some of these core proteins,  e.g., that of the 
cell surface proteoglycan syndecan (Saunders  et al., 1989), 
undergoes important changes during embryonic morphogen- 
esis, suggesting that HSPGs actively participate  in and may 
even modulate developmental processes (Bernfield and San- 
derson,  1990). 
Many of the functions of these proteoglycans,  however, de- 
pend on their polysaccharide moieties, whereby the number, 
length,  charge, and sequence complexity of the heparan sul- 
fate chains play an important role (Ruoslahti,  1989). These 
chains appear to vary, not only between different proteogly- 
cans, but also for different  representatives of a single pro- 
teoglycan species. To a certain extent this variability appears 
intrinsic to the molecular mechanisms that underlie the post- 
translational  modification of proteins in general, and the bio- 
synthesis of these complex carbohydrates in particular  (Lin- 
dahl et al., 1986). Yet, other variations  seem less fortuitous. 
Studies of syndecan,  for example,  have revealed changes in 
the type, number,  and the length of the glycosaminoglycan 
chains, depending on the source of the proteoglycan (Sander- 
son and Bernfield,  1988;  Salmivirta et al.,  1991) and the 
physiological  environment  of the cells (Rapraeger,  1989). 
An even more extreme example  is provided by serglycin, 
which is  substituted  with heparin  chains  in mastocytoma 
cells (Kjell6n et al.,  1989), but primarily with chondroitin 
sulfate  chains  in basophilic leukemia cells (Seldin  et al., 
1985),  indicating  that the carbohydrate moiety of the pro- 
teoglycan varies with the differentiation and functional status 
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text (Rapraeger, 1989), but the variables that influence these 
structural aspects of the proteoglycans  remain largely  un- 
known. Since the heparan sulfate chains determine the ma- 
trix, growth factor, and proteinase  inhibitor-binding activi- 
ties of the proteoglycans,  these structural differences may not 
be trivial and influence the adhesiveness, growth, and migra- 
tion of the cells,  and the outcome of the developmental 
processes that depend on these cellular  properties. 
The establishment of structure-function  relationships  in 
the proteoglycans  and the evaluation of their expression will 
therefore  necessarily  include the characterization  of their 
carbohydrate moieties. For a long time chemical and enzy- 
matic susceptibility tests have played an importam and exclu- 
sive role in this characterization.  More recently,  for chon- 
droitin  sulfate  (Couchman et al.,  1984;  Yamagata et al., 
1987), keratan sulfate (Caterson et al.,  1983), heparan sul- 
fate  (Kure and Yoshie,  1986),  and heparin  (Pejler  et al., 
1988), these approaches  have been supplemented  with im- 
munological assays using mAbs specific for epitopes that are 
unique to  these  glycosaminoglycans  or  their  degradation 
products.  In the present report we describe  two mAbs that 
extend this approach to the detection and characterization of 
the heparan sulfate proteoglycans.  One detects  intact hepa- 
ran sulfate  chains,  the other the desaturated uronates  pro- 
duced during the cleavage of the heparan sulfate chains with 
heparitinase, allowing the mapping of heparan sulfate and of 
the heparitinase-resistant  proteoglycan  cores in tissues and 
tissue extracts.  These antibodies  reveal that the expression 
of heparan sulfate undergoes important changes during em- 
bryonic development. 
Materials and Methods 
Biochemicals 
Heparin from porcine mucosa was  obtained from Calbiochem-Behring 
Corp. (San Diego, CA). Chondroitin sulfate A from whale cartilage,  chon- 
droitin sulfate B from pork skin, chondroitin sulfate C from shark cartilage, 
heparan sulfate from bovine kidney, and hyaluronic acid from human umbil- 
ical cord were obtained from Sigma Chemical Co. (St. Louis,  MO). Dex- 
tran and dextran sulfate  were  obtained from Pharmacia LKB  (Uppsala, 
Sweden).  Salmon sperm DNA was from Sigma Chemical Co. Heparinase 
(heparin  lyase,  EC  4.2.2.7),  heparitinaso  (heparan  sulfate  lyase,  EC 
4.2.2.8), chondroitinase ABC (chondroitin ABC lyase,  EC 4.2.2.4), and 
chondroitinase AC II (chondroitin AC lyase,  EC 4.2.2.5) were from Sei- 
kagaku  Kogyo  Co.  Ltd.  (Tokyo, Japan).  Proteinase K  was  from Merck 
(Darmstadt, Germany), and thermolysin from Calbiochem-Behring Corp. 
mAb 1B5 was a kind gift of Dr. Bruce Caterson (University of North Caro- 
lina, Chapel Hill, NC). 
Cell Culture 
Normal human fetal lung fibroblasts were cultured in DME (Gibco Europe, 
Paisley, Scotland, UK) supplemented with 10% (vol/vol) FCS. Labeling of 
confluent monolayers  with carrier-free 35IS]sulfuric acid (New England 
Nuclear, Boston, MA) in culture medium with reduced sulfate content was 
as described before (David and Van den Berghe, 1983). 
Heparan Sulfate Proteoglycan Isolation 
Heparan sulfate proteoglycans  were isolated from the detergent extract, ex- 
tracellular matrix, and the conditioned media of cultured human fetal lung 
flbroblasts  as described before (Lodes et al.,  1986).  Hydrophobic mem- 
brane-associated heparan sulfate proteoglycans  were purified by liposome 
incorporation,  followed  by gel  filtration on  Sepharose  CL4B  in 4  M 
guanidinium chloride, and by ion exchange chromatography on Mono Q in 
0.5%  Triton X-100, 6  M  urea, 50 mM Tris-HCl, pH 8.0 (Lodes et al., 
1987). Secreted heparan sulfate proteoglycans  from the matrix and media 
fractions were purified by cesium chloride density gradient centrifugation, 
ion-exchange chromatography on Mono Q, and gel filtration on Sepharose 
CL4B in 4 M guanidinium chloride (Heremans et al.,  1988). 
Enzymatic and Chemical Treatments 
Heparinase, Heparitinase, and Chondroitinase ABC Digestions. Purified 
samples of the heparan sulfate proteoglycans  or 200-#g aliquots of the 
different commercial glycosaminoglycans were digested for 3 h at 37~  with 
1 mU of heparinase, 1 mU of heparitinase, or 5 mU of chondroitinase  ABC 
in 0.1 ml of 100 mM sodium chloride, 1 mM calcium chloride, 50 mM so- 
dium hepes, pH 7.0, containing 5 #g of BSA. The pmteoglycan samples 
were digested in the presence of pmteinase inhibitors, as described before 
(David and Van den Berghe,  1985). 
Proteinase Digestion.  Pmteoglycan samples  were digested  for 2 h at 
65~  with 100 #g/ml of proteinase K in 50 mM Tris-HCl  buffer, pH 8,0, 
or with 100/xg/ml of thermolysin in 5 mM calcium chloride, 50 mM Tris- 
HCI,  pH 8.0. 
Desulfation,  Acetylation,  and Sulfation  Reactions.  Heparan sulfate 
proteoglycans  or heparin were dissolved in 1 M pyridinium chloride, 1 M 
guanidinium chloride, pH 5.2, and N-desulfated  by treatment with 19 vol 
DMSO for 4 h at 50~  as described before (David and Van den Berghe, 
1985). The N-desulfated samples were dissolved in 0.125 M sodium bicine, 
pH 9.0, and acetylated  as described before  (David  and Van den Berghe, 
1985) or resulfated  by treatment with 250 mM sulfurtrioxide-trimethyl- 
amine complex (Inoue and Nagasawa,  1976). Trinitrobenzene sulfonic acid 
was used to monitor the degree of substitution of the modified N-desulfated 
samples (Glazer et al.,  1975). 
Nitrous Acid Degradation.  1 vol of purified heparan sulfate proteogly- 
cans dissolved in water was mixed with 4 vol of ice-cold 0.5 M nitrous acid, 
pH 1.5, and left at room temperature (Shively and Conrad, 1976). After 10 
rain the sample was neutralized with sodium hydroxide and dialyzed against 
20 mM Tris-HC1, pH 7.4. 
Treatment  with Mercuric Acetate.  Proteogtycan  samples eluted from 
DEAE with 0.8 M  sodium chloride, 0.2 M  sodium acetate, pH 5.0, and 
heparitinase-digested  proteoglycan  samples in heparitinase buffer were 
miL~d with 3 vol of 0.1 M sodium acetate, 25 mM mercuric acetate, pH 
5.0, and left for 10 min at room temperature (Ludwigs  et al.,  1987). 
Reduction.  Heparitinase-digested  heparan sulfate  proteoglycans  were 
reduced with 1 M potassium borohydride for 2 h at room temperature. 
Radioiodination.  The proteoglycans were labeled using sodium 1251  and 
chloramine-T  as described before (Lories et al.,  1987). 
Isolation of the Hybridomas 
BALB/c  mice  were  immunized with  liposome-incorporated membrane 
heparan sulfate pmteoglycans (F58) or with heparitinase-digested  medium 
heparan sulfate proteoglycans  (F69) from human fetal lung fibroblasts. The 
immunization schemes and the protocols for cell fusion and hybridoma se- 
lection were as described before (De Boeck et al., 1987). The supematants 
of the hybridoma cultures were screened by immunodot blotting on Zeta 
probe membranes and by reverse  immunodot blotting using rabbit anti- 
mouse  Ig-coated  nitrocellulose  sheets  and  [35S]sulfate-labeled  or  1251- 
labeled heparan sulfate proteoglycan,  as described (De Boeck et al., 1987). 
Hybridomas F58-10FA and F69-3GI0 were subcloned twice by limiting di- 
lution. The corresponding mAbs were purified from ascites fluid by ammo- 
nium sulfate precipitation and gel filtration,  mAb lOF_,4 was identified as 
an IgM and mAb 3G10 as an IgG2b, using Mouse Typer (Bio-Rad Labora- 
tories, Richmond, CA). Other antibodies used were the antiglypican mAb 
S1 (De Boeck et ai.,  1987), the antiperlecan mAb 9C9 (Heremans et al., 
1989), and mAb 1135, which is directed against unsaturated urormte linked 
to N-acetylgalactosamine  (Couchman et al.,  1984). 
Proteoglycan Binding Assays 
mAb t0E4 was coupled to CNBr-activated  Sepharose (2 mg/ml gel) follow- 
ing the instructions of the supplier (Pharmacia LKB).  Aliquots (40,000 
cpm) of l~I-iodinated or [35S]sulfate-labeled proteoglycan or glycosamino- 
glyean were incubated with 20 #g immobilized antibody in the presence of 
0.5%  Triton X-100 and of various buffers,  salts,  and competitors (see 
Results)~ After overnight incubation at 4~  with mixing, the immunobeads 
were pelleted by centrifngation, and the radioactivity  was determined in the 
supernatam and pellet fractions. 
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cryosections and deparaffinated sections of tissues fixed  in 2% parafor- 
maidehyde were  overlaid  with 2.5 mU of heparitinase in 0.5 ml of buffer 
or with buffer  only,  for  2 h at 37~  After  rinsing  with  0.5 %  casein  (wt/vol) 
in PBS, the sections were incubated for 1 h (cryosections)  to 3 h (paraffin 
sections) with mAb 10E4 (5 #g/ml) or with mAb 3GI0 (2 #g/ml) in 0.5% 
casein-PigS, rinsed, and further  incubated  for 1 h with horseradish  peroxi- 
dase-conjugated rabbit anti-mouse Ig (Dakopatts, Glostrup, Denmark). 
After  rinsing, the sections  were  stained  using 0.05  % 3,3'  diaminobenzidine 
(wt/vol)  and 0.01% hydrogen  peroxide  (wt/vol).  In some  experiments  the tis- 
sue sections  were  treated  for 10 rain  at room  temperature  with 14 mM mer- 
curic acetate  at pH 5.0 (Ludwigs et al., 1987) before  or after the enzyme 
treatment, and then further  processed for immunocytochemistry. 
Results 
mAb IOE4 Reacts with Heparan Sulfate 
Several hybridomas were obtained after immunization with 
intact heparan sulfate proteoglycan. During the screening as- 
says  the  culture  supematant  from  hybridoma  10E4  was 
found to react with intact proteoglycan, but not with hepar- 
itinase-treated proteoglycan, which implied that the corre- 
spending epitope might reside in the heparan sulfate chains. 
This hybridoma was subcloned twice and its antibody was 
further characterized. 
In dot-blot assays, mAb 10E4 reacted strongly with hepa- 
ran sulfate proteoglycans from the culture medium of human 
fetal lung fibroblasts (Fig. 1, B/). It also reacted with heparan 
sulfate proteoglycans that were isolated from the detergent 
extracts (Lories et al., 1987) or from the detergent-insoluble 
matrices (Heremans et al., 1988) of these cells (not shown). 
Heparitinase treatment of the proteoglycans abolished their 
reactivity with mAb 10E4 (Fig.  1, B2), without interfering 
with the binding of the proteoglycans to the membrane, as 
revealed by the persistence of the signal obtained with mAb 
Sl (Fig. 1, D1 and D2), a mAb that reacts with the core pro- 
tein of glypican, a cell surface heparan sulfate proteoglycan 
that is shed to the culture medium (David et al., 1990). mAb 
10E4 also reacted with heparan sulfate chains that were iso- 
lated from these proteoglycans by extensive digestion with 
proteinase K  and precipitation with ethanol  (Fig.  2,  A/). 
Digestion with chondroitinase ABC did not affect the reac- 
tivity of the fractions (not shown). Treating the proteogly- 
cans (not shown) or the protein-free heparan sulfate chains 
with DMSO under conditions that selectively remove N-sul- 
fate, in contrast, completely abolished the reactivity (Fig. 
2,  .42).  Autoradiography to  detect the  residual  O-linked 
[35S]sulfate (-,50% of the total [35S]sulfate initially present) 
confirmed that the N-desulfated chains remained bound to 
the Zeta-probe membrane during the assay (Fig. 2 B). The 
reactivity of the  DMSO-treated  samples  was  restored by 
resulfation (Fig. 2, A5), but not by acetylation (Fig. 2, A3). 
Moreover, acetylation of the DMSO-treated samples pre- 
vented restoration of  the immunoreactivity by treatment with 
trimethylamine sulfurtrioxide complex (Fig.  2, A6).  Treat- 
ment with DMSO, in contrast, did not affect the reactivity 
of the proteoglycans with, for example, mAb S1, as reported 
previously (De Boeck et al.,  1987). As a whole, the effects 
of these different modifications confirmed that mAb  10E4 
was reacting with the glycosaminoglycan  moiety of the hepa- 
ran  sulfate  proteoglycans,  and  suggested  that  N-sulfate 
formed part of the epitope. 
Variables That Affect the Reactivity of mAb 10E4 
The reactivity of mAb  10E4 with heparan sulfate or with 
heparan sulfate proteoglycan was salt and pH sensitive. At 
physiological pH the binding of soluble labeled glycosamino- 
glycan or proteoglycan to immobilized 10E4 antibody was 
markedly reduced by concentrations of NaC1 >0.15 M, and 
virtually inexistent at NaC1 concentrations >0.25 M (Fig. 3 
A). At similar molar concentrations multivalent salts were 
more effective inhibitors than monovalent salts.  The bind- 
ing was also pH sensitive.  At physiological ionic strength 
(0.15 M NaC1), it was significantly reduced at pH values >7.6 
(Fig. 3 B). On the basis of these findings further binding ex- 
periments were conducted at pH 7.4 in the presence of 50 
mM NaC1. 
Specificity of mAb lOE4 
To assess the specificity ofmAb 10E4, the Sepharose-bound 
antibody  was  used  to  fractionate  35S-proteoglycans  pro- 
Figure I.  Enzyme and chemical susceptibilities of the epitopes. 
Heparan sulfate proteoglycans from the culture medium of human 
lung fibroblasts were spotted on Zeta probe membranes either with- 
out any pretreatment (lane 1), or after one of the following regi- 
mens: a treatment with heparitinase only (lane 2); with heparitinase 
first and then with borohydride (lane 3); with borohydride only 
(lane 4); with borohydride first and then with heparitinase 0ane 5); 
with  nitrous acid  only (lane  6);  with  nitrous  acid  followed by 
heparitinase (lane 7); with heparitinase followed by mercuric ace- 
tate  (lane  8);  or  inversely with  mercuric  acetate  followed by 
heparitinase (lane 9). The strips were exposed to either no first an- 
tibody (row A), mAb 10FA (row B), mAb 3G10 (row C), or mAb 
S1  (row D),  and  stair~l using  a  peroxidase-eonjugated rabbit 
anti-mouse  second antibody. 
Figure 2.  Reactivity of mAb 
10FA with  chemically  mod- 
ified heparan  sulfate chains. 
Protein-free  heparan  sulfate 
chains from metabolically la- 
beled proteoglycans were spored on Zeta probe membrane strips 
without any pretreatment (lane I), or after one of the following 
treatments: N-desulfation (lane 2); N-desulfation followed by acet- 
ylation of  the free  aminogroups (lane 3 ); exposure to sulfurtrioxide- 
trimethylamine complex; (lane 4 ); N-desulfation followed  by resul- 
fation with sulfurtrioxide 0ane 5); or N-desulfation followed by 
acetylation and then exposure to sulfurtrioxide 0ane 6). The strips 
were incubated with antibody 10E4 and stained using peroxidase- 
conjugated second antibody (row/1) and then exposed for autora- 
diography (row B). 
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Figure  3.  Salt  and  pH  sensitivity  of  the  heparan  sulfate 
proteoglycan-mAb 10E4 binding interaction. The membrane pro- 
teoglycan fraction from cultured human hmg fibroblasts was la- 
beled with ~2sI, and aliquots (40,000 cpm) were allowed to bind to 
Sepharose CIAB beads substituted with 10E4 antibody (6 ttg/assay) 
at different concentrations of either sodium chloride (o) or sodium 
sulfate (o)  (A), and at different pH values (B).  The inhibition 
curves obtained  with sodium phosphate and ammonium sulfate 
were superimposable on that obtained  with sodium sulfate (not 
shown). 
HS composition 
Source  Applied  Bound  Fall through 
(%) 
PG 
C  54.3  94.7  44.5 
M  31.6  83.9  21.5 
GAG 
C  51.6  96.0  40.4 
M  25.9  89.1  16.4 
The proteoglycans (PG)  from ~sSO4-1abeled human lung fibroblast  cell layers 
(C)  and  from  the  conditioned  culture  media of these cells  (M)  and  the 
glycosaminoglycans (GAG)  prepared from these proteoglycans by exhaustive 
protease treatment were mixed with Sepharose CIAB-coupled 10E4 antibody. 
After an overnight incubation the beads were collected, washed, and duted 
with 1 M sodium chloride. The heparan sulfate content of the applied, bound, 
and nonbound fractions was measured by cetylpyridinium chloride precipita- 
tion of control and nitrous acid-treated samples (David and Van den Berghe, 
1983),  and expressed as a percentage of the total  asS-GAG in each of these 
fractions. 
This result was consistent with the evidence that this proteo- 
glycan fraction is composed of multiple distinct proteogly- 
cans (Lories et al.,  1989), and indicated that the 10E4-reac- 
tive heparan sulfate chains were carried by all core proteins 
present in this fraction.  The specificity of mAb  10E4 for 
heparan sulfate was also apparent from competition experi- 
ments in which the 10E4 immunobeads were incubated with 
~zsI-iodinated heparan sulfate proteoglycan  or with 35S-labeled 
duced by cultured human fetal lung fibroblasts (Table I). 
Compared  with  the  composition of the  cell  extracts  and 
media fractions that were originally applied, the immuno- 
purified materials  were substantially enriched in  35S-hep- 
aran sulfate, whereas the fall-through fractions were partially 
depleted of 35S-heparan sulfate. When this fall through was 
reapplied to a fresh column, again part of  the heparan sulfate 
was bound (not shown). This indicated that mAb 10E4 pref- 
erentially retained heparan sulfate and heparan sulfate pro- 
teoglycan. On the other hand,  the fractionation of ~2SI-la- 
beled lipophilic proteoglyeans yielded  10E4-bound  label, 
which was retained near the origin during electrophoresis in 
SDS-polyacrylamide gradient gels, but which migrated as 
multiple sharp bands after heparitinase digestion (Fig. 4 A). 
Figure 4. Occurrence of the 10E4 and 3G10 epitopes in individual 
proteoglycans.  (A)  The  ~z~I-labeled cell  surface  proteoglycans 
from human lung fibroblasts, a mixture  of heparan  sulfate and 
chondroitin  sulfate  proteoglycans,  were  incubated  with  solid 
phase-immobilized mAb 10FA. Bound proteoglycans were eluted 
with salt and analyzed by SDS-PAGE  and autoradiography either 
without 0ane 1) or after digestion with heparitinase (lane 2). (B) 
Nondigested (lane/) and heparitinase-digested (lane 2) nonlabeled 
cell surface proteoglyeans were submitted to SDS-PAGE, blotted 
onto Zeta probe,  and  stained  with  mAb  3G10. The positions 
of fibroglycan (F),  glypican (G),  and  syndecan (S) have been 
indicated. 
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(Table II). In these binding experiments, chondroitin sulfate 
chains and casein at concentrations of 100  #g/ml had no 
effect. Heparan sulfate, in contrast, at this and even lower 
concentrations, was an effective inhibitor. Some commercial 
preparations of hyaluronate and dermatan sulfate were in- 
hibitory (Table H), but this activity  appeared due to contami- 
nation with heparan sulfate (Table l/I). The inhibitions were 
completely abolished by pretreating the glycosaminoglycan 
samples with heparitinase or with nitrous acid, while a pre- 
treatment with heparinase had only a  moderate effect.  A 
chondroitinase ABC treatment, in contrast, had no influ- 
ence on the inhibitory effect of these samples, further ruling 
out any reactivity of hyaluronate or dermatan sulfate itself. 
On a weight basis heparin was less inhibitory than heparan 
sulfate  (Table  II).  Its  inhibitory effect was  abolished by 
N-desulfation (Table II) and by heparinase (Table HI), but 
also by heparitinase, albeit less efficiently  (Table III). Various 
dextran sulfates were strong inhibitors, but dextran was not. 
Treating these dextran sulfates with heparitinase, heparinase, 
chondroitinase, or nitrous acid had no effect on their inhibi- 
tory activity (not shown). 
mAb 3GlO Reacts with Heparitinase-generated 
EUminase Reaction Products 
Several hybridomas were also obtained after immunization 
with  heparitinase-digested  heparan  sulfate  proteoglycan. 
The culture medium of hybridoma 3G10 was found to immu- 
noprecipitate heparitinase-digested 12q-iodinated proteogly- 
cans,  but  not  the  intact  12q-iodinated  or  metabolically 
35SO4-1abeled proteoglycans. This finding implied that the 
Table 1L J2SI-HSPG  and ~sS-HS Binding to mAb lOE4: 
Effect of  Anionic Polymers 
Bound label 
Compound added  1:~I  3sS 
(%) 
None  69.5  65.3 
Heparin  34.6  46.5 
N-desulfated heparin  62.2  60.6 
Ace.~ylated N-desulfated  heparin  63.3  61.4 
Hyaluronate  8.8  23.3 
Chondroitin sulfate 
A  -  64.9 
C  63.2  64.7 
B  44.8  - 
Dextran sulfate  0.1  10.8 
Dextran  67.7  - 
Heparan sulfate 
50  II.I  - 
20  33.0  32.7 
I0  41.5  - 
Casein  -  60.9 
Salmon sperm DNA  63.5  - 
125  Radioiodinated  heparan sulfate  proteoglycans  (I-HSPG)  and metabolically 
labeled heparan  sulfate  chains (ssS-HS) were incubated with Sepharose 
CIAB-coupled 10EA antibody in the presence of various co~ds.  All com- 
pounds were added at a concentration  of 100 ttg/ml,  except heparan sulfate, 
which was added at concentrations  of 50,  20,  and  10 ttg/ml.  The amount of 
label bound is expressed as a percentage of  the total label added to each incuba- 
tion mixture. 
Table III. ~251-HSPG  Binding to mAb lOE4: Effect of 
GAGs and GAG Oligosaccharides 
GAG added 
GAG 
treatmem  None  HA  DS  HP  HS 
None  60.4  8. I  37.5  32.0  33,0 
Chondroitinase ABC  -  5.7  37,1  31,8  33,0 
Heparitinase  -  57.2  58.4  41.4  56.7 
Heparinase  -  23.3  43.3  54.0  43.4 
Nitrous acid  -  56.3  -  52.8  - 
Commercial preparations of hyaluronate (HA), dermatan sulfate (DS), heparin 
(HP)  (1~ ~g/assay),  and heparan  sulfate (HS) (20/~g/assay)  were added to 
~2SI-HSPG-mAb 10E4 mixtures as intact polymers or after preincubation with 
either  cbondroitinase  ABC,  heparitinase,  heparinase,  or nitrous  acid.  The 
enzyme-treated GAGs were boiled and added as such. The nitrous acid treated 
GAGs were ethanol precipitated twice and redissolved in H2O before addition 
to the mixtures. The amount of rnAb 10E4-bound label is expressed as a per- 
cent of the total label added to each assay, 
mAb was reacting with epitopes resulting from or exposed 
by the heparitinase digestion. 
This reactivity ofmAb 3GI0 was confirmed in indirect im- 
munoperoxidase  dot-blot  assays.  Untreated  proteoglycan 
fractions that were stained by mAbs 10E4 and $1 (see above) 
went undetected by mAb 3G10 (Fig. 1, C/). A hepaxitinase 
treatment that abolished the reactivity of the proteoglycan 
fraction with mAb 10E4 (see above) induced a strong reac- 
tion with mAb 3G10 (Fig. 1, C2). Reduction of the hepariti- 
nase-treated proteoglycans with borohydride abolished the 
reactivity with mAb 3G10 (Fig. 1, C3). This treatment also 
abolished the reactivity with mAb $1 (Fig. 1, D3). mAb $1, 
which was known not to react with dithiotreitol-treated pro- 
teoglycans or core proteins (De Boeck et al.,  1987),  also 
failed to stain proteoglycans that were treated with borohy- 
dride before being treated with heparitinase (Fig.  1, D5). 
This sequence of treatments, however, did not prevent the 
proteoglycans from reacting with mAb 3G10 (Fig.  1, C5), 
which suggested  that the reduction affected  an epitope created 
by the heparitinase treatment itself. Treating the proteogty- 
can fractions with nitrous acid at pH 1.5 did not affect their 
reactivity with mAb 3G10. No reactivity was generated by 
nitrous acid treatment only (Fig. 1, C6), nor did nitrous acid 
treatment prevent the generation of the  3G10  epitope by 
heparitinase (Fig. 1, C7). The reactivity of mAb 10FA with 
these samples, in contrast, was abolished by nitrous acid, 
with or without heparitinase (Fig.  1, B6 and B7), whereas 
neither treatment affected the reactivity with mAb $1 (Fig. 
1, D6 and/77).  Finally, exposing the heparitinase-treated 
proteoglycans to mercuric acetate at pH 5.0 abolished their 
reactivity with mAb  3G10  (Fig.  1,  C8).  This treatment, 
which has been shown to eliminate the unsaturated uronic 
acids  generated by  eliminase  reactions  (Ludwigs  et  al., 
1987),  did not affect the epitope of mAb S1 (Fig. 1, D8 and 
D9) and did not prevent the generation of the 3G10 epitope 
by the heparitinase treatment (Fig. 1, C9). Additional experi- 
ments indicated that the 3G10 epitope could not be generated 
in heparan sulfate proteoglycans by treating the proteogly- 
cans with heparinase, nor in chondroitin sulfate proteogly- 
cans by treating them with chondroitinase AC or ABC (not 
shown), mAb 3G10 reacted with hepaxitinase-digested hepa- 
ran sulfate proteoglycans  isolated from the detergent extracts, 
the extraceUular matrices, or the culture media of cells of 
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heparitinase-digested membrane proteoglycans, mAb 3G10 
was staining the different core protein forms (Fig. 4 B). Fi- 
naUy,  the reactivity of heparitinase-digested proteoglycans 
with mAb 3G10 was inhibited by supplementing the incuba- 
tion with heparitinase-digested heparan sulfate chains,  but 
not by heparan sulfate or heparitinase added separately, nor 
by chondroitinase ABC-digested chondroitin sulfate chains 
(Fig.  5).  These results suggested that the epitope of mAb 
3G10 was formed, at least in part, by the desaturated uronic 
acid residues generated during the cleavage of the heparan 
sulfate chains by heparan sulfate lyase. 
mAbs lOE4 and 3GIO as Histochemical Probes 
Since the above results indicated that mAb  10E4 and, indi- 
rectly, mAb 3G10 were specific probes for heparan sulfate, 
we investigated whether both antibodies could be used to 
map this glycosaminoglycan in tissue sections. In cryosec- 
tions of adult human skin, for example, mAb 10E4 strongly 
demarcated the dermo-epidermal junction (Fig.  6 e). This 
was consistent with the occurrence of heparan sulfate-rich 
basement membrane proteoglycan at this  site,  as revealed 
with a mAb specific for the core protein of this proteoglycan 
(Fig. 6 b). mAb 10E4 also stained the contours of  the epider- 
mal keratinocytes (Fig. 6 e), consistent with the occurrence 
of  cell  surface-associated  heparan  sulfate  proteoglycans 
with similar localizations in these cells, as revealed with the 
glypican core protein-specific mAb $1 (Fig. 6 a). Pretreat- 
merit of the sections with heparitinase abolished the  10F_,4 
staining,  consistent  with  the  specificity  of the  antibody 
(Fig. 6 f). 
Figure 5.  Inhibition  of mAb  3(;10  binding  by  heparan  sulfate 
oligosaccharides. Heparan sulfate proteoglycans from the culture 
medium of human lung fibroblasts were digested with heparitinase 
and blotted onto Zeta probe strips. The strips were incubated with 
antibody 3G10 in the presence of either 10 (lanes 1 and 2) or 100 
(lanes 4 and 5)/zg of  heparan sulfate (row A) or chondroitin sulfate 
(row B), that had been left untreated (lanes 1 and 4) or that had 
been mixed and preincubated (lanes 2 and 5) with, respectively, 
heparitinase  (row A)  or chondroitinase ABe  (row B).  Control 
strips were incubated with mAb 3G10 in the absence of additives 
(A6) or in the presence of  the enzymes only (,'13  and B3), or without 
mAb 3G10 and any additives (B6). After washing away  the incuba- 
tion mixtures, all strips were incubated with a peroxidase-conju- 
gated second antibody. 
Figure 6. mAbs 10E4 and 3GI0 as histochemical probes. Unfixed 
cryosections of human  skin were  incubated with the  core pro- 
tein-specific antibodies S1 (a) and 9C9 (b) to reveal the distribution 
of glypican  (a cell  surface proteoglycan) and that  of a  matrix- 
associated heparan sulfate proteoglycan, respectively. Other cryo- 
sections were briefly fixed in 2 % paraformaldehyde and incubated 
for 1 h in heparitinase buffer with or without enzyme. The mock- 
treated (c, e, and g) and heparitinase-treated (d, f, and h) sections 
were further incubated either without first antibody (c and d), with 
mAb 10FA (e and f), or with mAb 3G10 (g and h). All sections 
were stained using peroxidase-conjugated anti-mouse  antibodies 
and diaminobenzidine. Bar, 10 t~m. 
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This  antibody  left  nonenzyme-treated sections  unstained 
(Fig.  6 g).  In contrast, it decorated the cell contours and 
matrix structures in heparitinase-treated sections, staining 
the keratinocytes, the dermo-epidermal junction,  and  the 
microvascular basement membranes of  the dermis (Fig. 6 h). 
Some  control  experiments  confirmed  the  histochemical 
specificity of  mAb 3G10. Strong epithelial and mesenchymal 
stainings obtained with m_Ab 3G10 on heparitinase-treated 
sections of hamster  embryos (Fig.  7  a)  were completely 
prevented by exposure to mercuric acetate (Fig. 7 b). Chon- 
droitinase AC-treated embryonic cartilage nodules, in con- 
trast, were not stained by mAb 3G10 (Fig. 7 c), but strongly 
stained by mAb  1B5 (Fig. 7 d), an antibody that has been 
shown to be directed against unsaturated uronate linked to 
N-acetylgalactosamine (Couchman et al.,  1984). 
The patterns and intensities of the stainings obtained with 
mAbs  10E4 and 3G10 were, however, not always superim- 
posable. In adult hamster kidney sections, for example, mAb 
10FA strongly stained the Bowman's capsule and the base- 
ment membranes of only part of the tubules, whereas the 
Figure  7.  Specificity of the 3GI0 antibody. Deparaffinated sec- 
tions of 14-d-old hamster embryos were incubated for 2 h with 
heparitinase (a and b) or with chondroitinase AC (c and d). One 
of the heparitinase-treated sections was posttreated with 15 mM 
mercuric  acetate  (b).  After further incubation with mAb 3GI0 
(a-c) or mAb 1135 (d), the sections were stained using peroxidase- 
conjugated rabbit anti-mouse antibodies. Treating the sections with 
mercuric acetate before the heparitinase treatment had no effect on 
the stainings of  control antibody or mAb 3G10-treated sections (not 
shown). Bar, 100/zm. 
Figure 8. Heterogeneity of  the heparan sulfate chains. Cryosections 
of adult hamster kidneys were briefly fixed with paraformaidehyde 
and treated with buffer only (a), with heparitinase (c), or with 
heparinase (b and d). The mock-treated and enzyme-treated sec- 
tions were incubated with mAb 10E4 (a and b) or mAb 3G10 (c 
and d), and stained with peroxidase-conjugated rabbit anti-mouse 
antibodies. Bar, 100/zm. 
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only weakly stained  (Fig.  8 a).  mAb 3G10, in contrast, 
strongly stained the glomeruli and stained all tubular base- 
ment membranes uniformly (Fig.  8 c). This suggested  that 
at these specific sites the heparan sulfate chains  contained 
less IOFA epitope, or that these chains,  although accessible 
for heparitinase,  did have 10FA  e  pitopes that were less acces- 
sible for the antibody.  Interestingly,  a heparinase treatment 
strongly reduced the reactivity of the basement membranes 
with mAb IOFA, except that of the Bowman's capsule (Fig. 
8 b). mAbs 3(310 and 10E4 appeared, therefore,  to be useful 
to probe the tissular distribution of heparan sulfate and to 
map regional differences in the structure or exposure of this 
glycosaminoglycan. 
Developmental Changes in Heparan 
Sulfate Expression 
Both antibodies were then used to investigate the expression 
of heparan sulfate during embryonic development,  where the 
programmed changes in cell growth, cell adhesion, and ma- 
trix assembly that are instrumental  in the shaping of the body 
plan are thought to depend, at least in part, on heparan sul- 
fate-catalyzed processes. 
Expression of the 10E4 Epitope.  Staining  tissue sections 
of 8-13-d hamster embryos with mAb lOE4 revealed out- 
spoken temporal and regional  differences  in the abundance 
of this heparan sulfate epitope (Fig.  9, a-g). The strongest 
stainings  were obtained during early developmental stages, 
with particularly intense reactions in certain areas of the 
brain and in the mesenchymal tissues of the head, limbs, 
lungs, gut, and kidneys. In these mesenchymes the staining 
was most intense in the juxtaepithelial areas.  Staining  also 
occurred on basement membranes, but the epithelial  cells 
themselves were only moderately stained and,  except for 
some areas of  the ectoderm, in later stages even mostly nega- 
tive. Some of these localizations  and changing patterns were 
investigated  in  greater  detail  and  illustrated  at  higher 
magnifications  (Figs.  10-12). 
Nervous Tissues. In the 8-d embryo, the contours of virtu- 
ally all cells of the neural tube were distinctly outlined by the 
antibody (Fig. 10 a), but in later stages, most cells of the cen- 
tral nervous system had lost their stain (Fig. 9). A striking 
exception was formed by the telencephalic  areas, where the 
10FA epitope persisted up to day 13 on the cells that formed 
the walls of the lateral ventricles  (Fig.  10 b). In contrast to 
the central nervous tissues, the peripheral  nerves and the 
ganglia were strongly positive for 10FA (to a certain extent 
this can be seen in Fig.  9 d). 
Mesenchymal 7Issues. The 10FA epitope was also abun- 
dant on the mesenchymal tissues of the maxiliar and man- 
dibnlar processes of the 8-13-d embryo, where it ultimately 
became concentrated on the subectodermal cells, particu- 
larly those underlying the vibrissal rudiments (Fig. 11, a and 
c), on the dental mesenchyme, and on the cells of the tongue 
that condensed around the papillae and those that differen- 
tiated into muscle cells (Fig.  9). Strong  and changing  pat- 
terns of 10E4 staining  were also observed in the limbs.  In 
the 9-10-d embryo the whole mesenchyme of the limb bud 
was strongly and diffusely positive for 10FA (Fig.  10 c), but 
in later stages and at the level of the extremities,  the stain 
was mainly concentrated over the immediately subectoder- 
real mesoderm and over the myotendinous structures (Fig. 
10 d). For the mesenchymes of the visceral organs, particu- 
larly strong reactions were obtained in the lungs (see Figs. 
9 and 12). At day 10 the lung mesenchyme was strongly and 
nearly homogeneously decorated by the antibody (Fig.  12 
a). With further development strong 10E4 stain persisted on 
the mesenchymal cells that were in the immediate vicinity 
of the secondary and tertiary branches and growing tips of 
the lung  epithelium,  but the mesenchymal cells that  sur- 
rounded the major branches were only weakly stained (Fig. 
12, b and c). In the terminal  stages a light and diffuse stain 
occurred in the alveolar septae and in the basement mem- 
branes of the airway ducts (Fig.  12 d). In comparison with 
lung, the mesenchymes of the kidneys and other viscera were 
only moderately stained by the 10FA antibody, but as in lung 
this  stain  was mostly concentrated over the mesenchymal 
cells that were in contact with the epithelia and over the base- 
ment membranes  that  formed the  interfaces  between the 
mesenchymal and epithelial  tissues.  In the ll-d kidney, for 
example,  the 10FA stain was mostly concentrated over the 
pretubular mesenchymal cell aggregates  that subsequently 
form the S-shaped bodies and fuse with the branctdng ureter 
tree  and  over  still  undifferentiated  peri-ureterai  mesen- 
chymal cells (Fig.  10 e). In later stages of kidney develop- 
ment, the stain was virtually limited to the basement mem- 
branes (Fig.  10 f). 
Epithelial ~sues.  In general,  and in comparison with 
these mesenchymal stainings,  the epithelial  cell surfaces of 
endodermal  and  mesodermal  origin  were  only  weakly 
stained by the 10FA antibody (see, for example,  the kidney 
and lung epithelium in Figs. 10 and 12), and this staining was 
mostly limited to the earliest stages examined.  The ectoder- 
mal staining patterns,  in contrast, were more heterogeneous 
and complex. The very early flattened ectoderm was virtu- 
ally unstained by mAb  10FA. Later,  when these cells as- 
sumed a cuboidal shape they became positive for the 10FA 
epitope, but the overlying periderm was negative (Fig. 10 g). 
Finally,  in the multilayered  epiderm the basal cells were 
moderately stained, and the middle layers were even strongly 
stained by the antibody,  but the upper layers  were nega- 
tive (Fig.  10 h).  In some areas,  however, the entire thick- 
ness  of the  epithelium  was only weakly stained  or even 
negative for 10E4. These striking exceptions occurred at the 
level of the epiderm of the face (Fig.  11, a  and c), and at 
the level of the limb extremities,  where the epiderm of the 
dorsal side of the digits was strongly stained, but the lateral 
and volar sides were virtually negative (Fig.  11 e). For all 
these localizations  a treatment  of the sections with hepari- 
tin_ase completely abolished the staining  reaction  for the 
10E4 epitope (not shown). 
Expression of the 3G10 Epitope. To a certain extent,  the 
staining  pattern  obtained by mAb 3G10  on heparitinase- 
Figure 9. Developmental  changes in heparan sulfate expression. Sagittal sections of paraffin-embedded 9- (a), 9.5 (b), 10- (c), 11- (d), 
12- (e), and 13-d (f-h) hamster embryos were stained with the anti-"chain" mAb 10E4 (a-g), or treated with heparitinase and stained 
with the anti-%tub" mAb 3G10 (h). Indirect immunoperoxidase staining, g and h are negative prints. Bars, 100/~m. 
David et al. Antibodies  to Heparan Sulfate  969 Figure 10. Temporal and regional differences in heparan sulfate expression. Paraffin sections of hamster embryonic tissues stained with 
the anti-"chain  ~ mAb 10FA, showing the general neural tube staining at 8 d (a) and the localized staining of the lateral ventricle at 13 d 
(b), the strong diffuse staining of the hind limb bud at 9.5 d (c) and the localized foot stalnings at 12 d  (d), the staining of the kidney 
mesenchyme and basement membranes at 11 (e) and 14 d (f), and the staining of the surface ectoderm of the chest area at days 11  (g) 
and  13 (h) of development. Bars,  100/~m. 
The Journal of Cell Biology,  Volume 119, 1992  970 Figure H. Regional  differences  in embryonic heparan sulfate chain composition or exposure. Paraffin  sections through the lips and vibrissae 
(a--d), and through the digits (e and f) ofa 13-d hamster embryo, left untreated and stained with the anti-"chain" mAb 10E4 (a, c, and 
e), or treated with heparitinase and stained with the anti-"stub" mAb 3G10 (b, d, and f). Bars, 100/~m. 
treated sections mimicked the distribution of the 10E4 epi- 
tope in nonenzyme-treated embryonic tissues, with accentu- 
ated stainings of the walls of the lateral ventricles, the lungs, 
and, for example, the foot process (compare Fig. 9, g and h). 
However, in general, the patterns were less contrasted, the 
3G10 epitope being more widely and evenly distributed over 
the cell surface and matrix structures than the 10E4 epitope. 
In the central nervous tissue the 3G10 antibody also slightly 
stained the mesencephalic, cerebellar, and spinal structures. 
In the mesenchymes the 3G10 stain was less confined to the 
periepithelial  condensations,  and  several  epithelia  were 
moderately to strongly positive for 3G10,  where they had 
been virtually negative for the 10E4 epitope. This was exem- 
plified in the tissues of the face and digits, where virtually 
all ectodermal and mesenchymal cells, except those of carti- 
lage, were nearly homogeneously decorated by mAb 3G10 
(Fig.  11, b, d,  and f), not or imperfectly reproducing the 
mesenchymal  concentrations and the dorso-volar ectodermal 
polarization noted with the 10E4 antibody (Fig. 11, a, c, and 
e). These discrepancies suggested that some of the patterns 
obtained with the 10F_,4 antibody were to be explained by the 
local accumulation of heparan sulfate chains with a distinc- 
tive structure rather than by an increased density of heparan 
sulfate chains at these sites. As a whole, these data provided 
clear evidence for a differential and regulated expression of 
heparan sulfate during development. 
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In this report we describe the properties of two anti-heparan 
sulfate rnAbs that, especially when used in conjunction with 
each other and with core-specific probes,  provide unique 
tools for investigating the structure and expression of the 
heparan sulfate proteoglycans. The study of the distribution 
of the corresponding epitopes in embryonic tissues suggests 
that the expression of heparan sulfate is highly regulated. 
An Antibody against Native Heparan Sulfate Chains 
One of these antibodies (mAb 10E4) reacts with an epitope 
that occurs in native heparan sulfate, and that seems to be 
determined, at least in part, by the N-sulfate residues that are 
characteristic for this type of glycosaminoglycan. This con- 
clusion is based on the observations that the reaction of the 
proteoglycans with this antibody is abolished by nitrous acid 
or heparitinase; that protein-free heparan sulfate chains bind 
to the antibody; and that the reactivity of the proteoglycans 
or chains is  abolished by selective N-desulfation and re- 
stored by resulfation. The salt and pH sensitivity of  the bind- 
ing suggests that the interaction of the glycosaminoglycan 
with the antibodies is largely electrostatic in nature. This is 
consistent with the notion that the epitope comprises N-sul- 
fate, and suggests that binding may involve a critical histi- 
dine residue (the only amino acid with a pK near 7.0) on the 
antibody. Yet, despite involving ionized structures, the inter- 
action is endowed with remarkable specificity. The antibody 
does not react with DNA or hyaluronate, or with sulfated 
glycosaminoglycans such as chondroitin sulfate and derma- 
tan sulfate, which have similar average charge densities as 
heparan sulfate. The binding properties of this antibody are 
therefore more discriminating than those of the "natural" 
anti-heparan sulfate antibodies frequently encountered in 
patients with systemic lupus erythematosus, which most of- 
ten  recognize heparan  sulfate and  double-stranded DNA 
(Faaber et al., 1986; Aotsuka et al., 1988).  The precise na- 
ture of the epitope, however, remains undefined. The occur- 
rence of N-sulfate is not sufficient and may even not be an 
absolute requirement for interaction with mAb  10FA. In- 
deed, heparin, which compared with heparan sulfate is much 
more enriched in N-sulfate, is a less effective inhibitor than 
heparan sulfate in the binding assays.  On the other hand, 
dextran sulfate, which has no N-sulfate, is one of the most 
effective inhibitors. Since there are no known modifications 
of the heparosan polymer that are present in heparan sul- 
fates but not in heparin, this observation suggests that recog- 
nition by the antibody requires both the presence of N-sul- 
fate, and the absence of further modifications that may occur 
in the glucosamine and vicinal uronate residues after the ini- 
tial  N-deacetylation and  N-sulfation  reaction.  Then,  the 
heparitinase  and  nitrous  acid-sensitive  contaminants  in 
some hyaluronate preparations  that are  inhibitory for the 
binding of the antibody could possibly represent the other 
end of the spectrum and be lowly sulfated heparosan chains 
with  intermediate  degrees  of chain  modifications and  a 
Figure 12. Changing patterns of heparan sulfate expression during 
lung development. Paraffin sections through the lungs of 10- (a), 
11- (b), 13- (c), and 14-d (d) hamster embryos, stained with the 
anti-"chain" mAb 10E4. Bars, 100 #m. 
The Journal  of Ceil Biology,  Volume 119, 1992  972 higher incidence of the epitope than characteristic heparan 
sulfate chains, but this was not further investigated. In a 
sense, the specificity of the antibody and its preference for 
heparan  sulfate over heparin mimics that of the  enzyme 
heparitinase.  This enzyme cleaves the or-glycosidic  bonds 
between N-sulfated or N-acetylated glucosamines and gluc- 
uronic acid, and therefore depolymerizes heparan sulfate ex- 
tensively while leaving heparin mostly undegraded (Hovingh 
and Linker,  1970).  It is  significant, in this context, that 
heparitinase is actually destroying the  10E4  epitope  (see 
Table llI) and not just removing it from the preparation by 
cleaving the chains between the epitope and the protein link- 
age region. However, heparinase, which cleaves ot 1,4-glyco- 
sidic bonds between N-sulfated glucosamines and 2-O-sul- 
fated iduronates, also destroys some 10E4 epitopes in the 
heparan  sulfate preparations  and abolishes the  inhibiting 
structures in heparin more effectively than heparitinase (Table 
HI). This may be an indication that in the build up of the epi- 
tope there is some tolerance as to the nature of the uronates 
to which the N-sulfated glucosamines are linked, but that 
further O-sulfation of the N-sulfated glucosamines (which 
happens more extensively in heparin than in heparan sulfate) 
abolishes their reaction with rnAb 10E4. On the other hand, 
the strong inhibitory activity of dextran sulfate implies that, 
to a certain extent, the recognition sequence may also be 
mimicked in this polymer. To propose that the natural recog- 
nition  sequence  must  therefore  also  comprise  O-sulfate 
would seem contradictory to the conclusions drawn from the 
results obtained with heparin. Possibly the epitope is mim- 
icked in dextran sulfate because it includes sulfated glucose 
derivatives that are engaged in an o~-glycosidic bond. Such 
sequences are present in the heparinoids and dextran sulfates 
but in none of the other natural glycosarninoglycans tested. 
The or-glycosidic  linkages by themselves, however,  do not 
suffice to form the 10E4 epitope, since N-desulfated heparan 
sulfates and unsulfated dextran are not recognized by the 
antibody. On the other hand, both the dextran sulfates and 
heparan sulfates are made up of the alternation of regions of 
high sulfation with bloc regions of low or no sulfation (Gal- 
lagher and Walker,  1985; Turnbull and Gallagher, 1990).  If 
these alternations were important for the reactivity with the 
10E4  antibody, it would account for the observation that 
heparin, wherein these sulfate-free regions occur less fre- 
quently, is less well recognized. Clearly, further character- 
izations are needed. As a whole, the specificity of the 10E4 
antibody may mimic that of mAb HK-249,  a  mAb raised 
against the proteoglycan produced by the Engelbreth-Holm- 
Swarm tumor, believed to recognize a glucosamine sulfate 
otl,4-glucuronic acid-containing determinant in the intact 
chain of the proteoglycans (Snow et al.,  1990).  It would 
seem different, however, from that of rnAb Hep SS-1, which 
is thought to recognize an O-sulfated, N-acetylated glucos- 
amine linked to uronic acid (Kure and Yoshie,  1986). 
The repetitive but nonuniform structure of  the heparan sul- 
fate polymers then implies that individual heparan sulfate 
chains are likely to contain multiple but variable numbers of 
the 10E4 epitope, and that different segments of the polymer 
may react differently with the antibody. The segment adja- 
cent to the protein linkage region, for example, consists of 
an extended N-acetylated sequence (Lyon et al., 1987),  and 
is not recognized by the antibody (Fig. 1). Also, the residual 
staining  of some  basement  membranes  after  heparinase 
treatment, where the reactivity of the mesenchymal matrix 
and that of the cell  surfaces is  abolished (Fig.  8),  indi- 
cates that the relative positions of the  10E4  epitopes and 
heparinase cleavage sites with respect to the linkage region 
must be different at these different sites. On average, how- 
ever, the 10E4 antibody is expected to trace the mass ofhepa- 
ran sulfate expressed on individual proteoglycans and at in- 
dividual sites. 
An Antibody That Traces  Residual 
Heparan Sulfate Stubs 
mAb 3G10, in contrast, does not react with the intact hepa- 
ran sulfate chains. It appears to be directed, but only in part, 
against  the  desaturated uronate  residues  generated  by  a 
heparitinase treatment. The effect of the mercuric salt indi- 
cates that the uronate is an essential component of the epi- 
tope.  The  absence  of  reactivity  of  the  antibody  with 
heparinase-treated heparan sulfate proteoglycans, or chon- 
droitinase ABC- and AC-treated chondroitin sulfate pro- 
teoglycans, however,  suggests that this A-uronate is recog- 
nized in a specific context. The specificity of heparitinase, 
which cleaves the chains at the level of the 2-acetamido and 
2-sulfamido-2-deoxy-D-glucosyl o~(1-4) D-glucuronate link- 
ages, and the structure of the heparan sulfate chains, which 
is rich in extended N-acetylated sequences in the region ad- 
jacent to the protein linkage, suggest that this context is an 
N-acetylated glucosamine. This context would indeed ex- 
plain why nitrous acid degradation of the chains before the 
enzyme digestion (leaving only N-acetylated sequences at- 
tached to the cores) has no effect on the amount of 3G10 epi- 
tope generated in the core protein preparation. The failure 
to detect any cross-reactivity of 3G10 with chondroitin sul- 
fate proteoglycans that have been extensively digested with 
chondroitinase AC,  an enzyme that can depolymerize the 
chondroitin sulfate chains down to the initial glucuronate, 
which  is  linked  to  the  gal-gal-xylose  linkage  sequence 
(thought to be common to chondroitin sulfate and heparan 
sulfate chains), is also significant in this context. It means 
either that the heparitinase preparation cannot depolymerize 
the heparan sulfate chains down to this initial glucuronate, 
leaving a desaturated heparosan disaccharide to react with 
3G10, or that the antibody is recognizing a difference be- 
tween the desaturated uronate on the linkage region of hepa- 
ran sulfate and that of chondroitin sulfate chains. The first 
possibility would be  reminiscent of the activity of chon- 
droitinase ABC on chondroitin sulfate chains, as this en- 
zyme, unlike chondroitinase AC, always leaves a desaturated 
chondroitin (sulfate) disaccharide attached to the glucuronic 
acid-gai-gal-xylose linkage region (Christner et al.,  1980). 
The second possibility would be of potential interest as it is 
not known what signals direct a cell to extend the linkage re- 
gion by either heparosan or chondroitin sequences. Yet the 
3G10 antibody also reacts with heparan sulfate oligosaccha- 
rides liberated from Sepharose CL4B-coupled proteoglycan 
by heparitinase, indicating that the linkage sequence itself is 
not required for the epitope (not shown). 
Irrespective of  the precise context in which the desaturated 
uronates are recognized by 3G10, only one desaturated uron- 
ate residue per chain will remain linked to the core protein. 
The extent to which 3G10 reacts with heparitinase-treated 
core proteins or tissue sections will therefore trace the hum- 
￿9 x~..:~  ~,  ~1  A~*;k~;Dc  tn  14pnnran  ,~ulftlte  973 ber of heparan sulfate chains  carried by these cores or ex- 
pressed in a particular tissue rather than the mass of heparan 
sulfate that was originally  present. 
Differential Expression of Heparan Sulfate 
Not unexpectedly, the surfaces and extracellular  matrices of 
virtually all adherent  cells in adult and embryonic animals 
are stained by either one or a combination of both these anti- 
bodies, revealing the occurrence of heparan sulfate at these 
sites. However, the intensity of the staining reactions  shows 
marked  tissue  and  stage-dependent  variations,  suggesting 
that the expression of heparan sulfate is highly regulated and 
subject to both temporal and spatial  controls.  In general, 
heparan sulfate seems to abound in the early embryo, espe- 
cially in the mesenchymal tissues of those areas that undergo 
active morphogenesis,  and is less conspicuous in the tissues 
of the healthy  adult.  This evidence for a developmentally 
controlled expression  of heparan  sulfate  seems consistent 
with the data on the differential and regulated  expression of 
the core proteins of the cell surface proteoglycans  syndecan 
(Bernfield and Sanderson,  1990) and fibroglycan  (David et 
al., unpublished results) in embryonic tissues and in healing 
wounds (Elenius  et al.,  1991). However, the distribution  of 
these two cell surface proteins in the embryo overlaps only 
partially with that of  the 10E4 and 3G10 epitopes, suggesting 
that additional proteoglycans  may be involved and under de- 
velopmental control,  or that  the substitution  of these pro- 
teoglycans  with heparan  sulfate is not uniform,  or both. A 
striking  example is provided in the developing lung,  where 
syndecan and fibroglycan are mainly expressed in,  respec- 
tively,  the lung  epithelium  (Brauker  et al.,  1991) and the 
mesenchymal  cells that  surround the epithelial  stalks  and 
branches,  but where the 10FA epitope, in contrast,  abounds 
on the mesenchymal  cells that confront the tips of the ex- 
panding epithelium  (Fig.  12). The involvement of additional 
proteoglycan forms might  be expected from the complex 
composition of the cell surface proteoglycan fractions  from 
most cell types, including fetal lung fibroblasts (Fig. 4), and 
from the recent identification  of additional  members of the 
syndecan-fibroglycan  family  (Carey  et al.,  1992;  David et 
al., 1992; Gould et al., 1992; Kojima et al., 1992), whereas 
direct evidence has been obtained for the variability  of the 
glycanation of syndecan during lung development.  From day 
12 to 18 of development,  the relative mass of syndecan in the 
mouse embryonic lung was noted to decrease progressively, 
due to a reduction in the size of its glycosaminoglycan  chains 
(Brauker  et al.,  1991), which is not inconsistent  with the 
progressive reduction in 10E4 staining of  the respiratory epi- 
thelium  noted  here  over a  similar  time  frame  (Fig.  12). 
Moreover, the results obtained in the embryos (Fig.  11) and 
in the adult kidney sections (Fig. 8) indicate that the distribu- 
tions of the 3G10 and 10FA epitopes do not always coincide. 
This finding could be interpreted as discrepancies in epitope 
exposure,  but may also reflect  regional  differences  in the 
structure of the proteoglycans,  for example,  with respect to 
the length  or the sulfation  (heparin  likeness)  of the chains 
that  are implanted  on the cores.  Such regional  differences 
may be physiologically  meaningful,  for example, for the lo- 
cal activity and stability of growth  factors in the embryo 
(Klagsbrun  and Baird,  1991), or for the permeability of the 
matrix in kidney tissues specialized in transport phenomena 
(Kanwar et al.,  1980). In that context it may be interesting 
to note that the distribution  of the 10FA rather than the 3G10 
epitope in the 13-d hamster embryo resembled that reported 
for basic fibroblast growth factor in the rat embryo at a simi- 
lar stage of development (Gonzales et al., 1990). The hepa- 
ran sulfate sequences involved in growth factor binding and 
activation  are unknown but the sequence requirements  for 
the high  affinity  binding  interaction  between heparin  and 
antithrombin  indicate how important also the fine structure 
of these complex polysaccharides can be for proteoglycan 
function (Lindahl et al., 1986). Antibody probes that would 
be able to trace a variety of defined heparan sulfate sequences 
would therefore be important additions  to the present anti- 
body panel, and find wide applications  in the in situ map- 
ping  and probing of heparan sulfate during  developmental 
processes. 
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